mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma

201285 citationsJournal Articlebronze Open Access

Authors

Alexandra Faustino · Universidade do Porto

Joana Couto · Universidade do Porto

Helena Pópulo · Universidade do Porto

Ana Sofia Rocha · Universidade do Porto

Fernando Pardal · Hospital de São Marcos

José Cameselle‐Teijeiro · Universidade de Santiago de Compostela

José Manuel Lopes

Abstract

We determined that the AKT/mTOR pathway is particularly overactivated in human cPTC harboring the BRAF(V600E) mutation. Moreover, our results suggest that the mTOR pathway could be a good target to enhance therapy effects in certain types of thyroid carcinoma, namely in those harboring the BRAF(V600E) mutation.

Topics & Keywords

PI3K/AKT/mTOR signaling in cancer Thyroid Cancer Diagnosis and Treatment Coagulation, Bradykinin, Polyphosphates, and Angioedema

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 97, Issue 7, pp. E1139-E1149

DOI: 10.1210/jc.2011-2748

Field-Weighted Citation Impact: 5.25